valu usd unless otherwis note
boost thought mean
view after-market pre-announc strong earn
came above-consensu revenu number across segment
well oper incom thesi see
volum support over-the-counter drug/inf formula busi
pandem ii market share gain recess
side given lower price store brand pre-announc point
support first point reiter op
make announc coupl notabl
thing pre-announc upsid consist iri data trend
rx script proxi commentari link also came
broad base strength across three busi csca/otc
bigger question go around carry-through
beyond versu stockpil revers ii call
guidanc remain unchang given uncertainti current oper
environ relat unclear suggest
absent outlook would rais pull
given earli time would expect increas also think
go uniqu leav exist guidanc unchang
least across pharma/specialti univers iii get lot
question around posit includ last night well own
debat think updat push share higher
us resili forecast pandem
store brand over-the-counter share gain support move
rais forecast reflect pre-announc rang
pull forecast back lower end full-year guidanc
out-year number larg unchang exhibit provid
updat forecast take ep guidanc
leav est larg unchang
sever increment pocket potenti upsid
number includ ranitidin withdraw could help boost
omeprazol forecast link ii diclofenac approv link
repres potenti tailwind reflect new csca
launch year revenu could add ep iii
potenti rx upsid took conserv view strength
help gener proair us re-think hold
flat would add ep number
focu next get iri data tue give us color
over-the-counter growth momentum apr report earn
last week apr apr apr also previous
set time irish high court hear updat remain big
price prior trade day market close estimate unless otherwis note
stabl long-term outlook well posit current
unknown environ attract rel posit
see demand underli product unlik
materi impact move econom downturn
recess lower-pric store brand portfolio over-the-counter
product potenti pick market share past
downturn final view tax overhang like lift
year improv financi flexibl
driver thesi
organ csca growth like remain lower level
near term base busi eros like remain
overal see stabl revenu growth
csci oper margin expans continu
next year offer addit ep support
gener rx still expect separ time
seem unclear assum remain consolid
valuat like dictat valu market
place remain-co consum busi
think rel see appreci
given rel posit current downturn
upsid risk success separ sale rx
drive premium asset acceler new launch
activ across over-the-counter rx fda approv new larg
over-the-counter categori switch favor quicker-than-
expect resolut irish tax disput ir nopa
downsid risk slowdown core csca revenu
impact overal busi assum
greater dis-synergy/dilut rx separ
expect unfavor outcom irish us tax
upcom potenti catalyst updat around spin
potenti bolt-on accret use
capit clariti tax issu
bloomberg capit market estim upside/downside/target
base-cas scenario see stock impli
price-to-earnings ep
low-single-digit growth csca driven larg
recent oral self-car acquisit annual flattish
declin oper margin across platform near-
term driven step-up invest return growth
time
debt pay-down excess cash share repurchas
linger overhang irish tax disput ir nopa
weigh share price
upsid case scenario see stock impli
price-to-earnings ep
mid-single-digit better organ revenu growth
oper margin expans across platform
debt pay-down excess cash re-introduc accret
favor resolut irish ir tax disput
downsid scenario see stock impli
price-to-earnings pro forma ep
step-up invest fail pay contribut lower
oper margin time
model
particularli rx
exhibit segment build
 segment build self-car ranir sale million synergi exp gross distribut oper oper per management flattish margin bc investmentssal growth stop declin revers futuredistribut sg mix profit mix incom mix self-car inclus ranir intenational gross ranir lower gm intenational rest biz neutral omdistribut oper oper sale growth ranir gmdistribut sg expans next year sale mix profit mix incom mix
exhibit segment build cont
 segment build y/i growth vs gross distribut oper oper y/i growth vs meaning declin sale growth sg mix profit mix incom mix corpor cost across platform
exhibit forecast
 incom self-car consum self-car prescript y/i growth vs total revenu net sale growth organ growth growth y-i growth driven acquisitionscost total gross profit gross portion invest dsg oper incom excl invest close target oper incom incom tax provis incom net incom ep non-gaap adj dilut ep share fulli dilut share ebitda ebitda analysi growth beyondadjust net margin expens net incom pharmaceuticals/specialti
price target base blend price-to-earnings ev/ebitda multipl use cy
estim assum multipl respect taken histor
averag global consum multipl price-to-earnings ev/ebitda made adjust
base company-specif attribut private-label discount earn momentum gener
busi discount litig risk collect result valuat discount
impli return price target support outperform rate
risk rate price target
organ revenu growth consum self-car america segment soften due
weaker-than-expect over-the-counter market growth greater-than-expect price eros
delay fda approv gener drug applic result declin revenu and/
margin rx segment
unexpect meaning competit entri us store brand over-the-counter rx busi
lead store-brand over-the-counter manufactur us market share compani
also particip pharmaceut market domest intern
omega deal ad ex-u exposur often compar larg global
manufactur realiti direct comp given diversifi busi model
encompass consum healthcar brand consum healthcar rx compani
acquir brought lower tax structur royalti stream tysabri sold
royalti pharma set platform intern expans
